MicroRNA-216a: a potential therapeutic target for drug resistance and recurrent of liver cancer

Hepatobiliary Pancreat Dis Int. 2013 Dec;12(6):661. doi: 10.1016/s1499-3872(13)60104-6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / physiopathology
  • Drug Resistance, Neoplasm*
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / physiopathology
  • MicroRNAs / antagonists & inhibitors*
  • MicroRNAs / drug effects
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / physiopathology
  • PTEN Phosphohydrolase / physiology
  • Phosphatidylinositol 3-Kinases / physiology
  • Proto-Oncogene Proteins c-akt / physiology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Transforming Growth Factor beta / physiology

Substances

  • Antineoplastic Agents
  • MIRN216 microRNA, human
  • MicroRNAs
  • Transforming Growth Factor beta
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • PTEN Phosphohydrolase